Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Zacks Investment Research

14 Jul 2026, 16:40 UTC · 2h ago

HRMY vs. AMGN: Which Stock Is the Better Value Option?

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

What the story claims

3 claims · each scored for market impact

What matters in this story

1
Harmony Biosciences Holdings (HRMY) currently holds a Zacks Rank of #1 (Strong Buy) and a Value grade of A. — A Strong Buy rating paired with a top value grade suggests significant upside potential for the specific ticker.
+0.40
2
Harmony Biosciences has a forward P/E ratio of 10.91 and a PEG ratio of 0.33, compared to Amgen's forward P/E of 16.25 and PEG of 3.58. — The significantly lower PEG ratio for HRMY indicates it is substantially undervalued relative to its expected growth compared to AMGN.
+0.20
3
Amgen (AMGN) currently holds a Zacks Rank of #3 (Hold) and a Value grade of C. — A 'Hold' rating and mediocre value grade indicate a lack of immediate catalyst or an overvalued state compared to peers.
-0.10